Please assess the completion status of the following clinical trial:

Trial Title: Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Metastatic colorectal cancer and failure to standard therapies (5-fluorouracil, irinotecan, oxaliplatin, anti-vascular endothelium growth factor, anti-epidermal growth factors in patients with RAS wild type tumors). A previous line with regorafenib is not required.~2. Elevated CEA serum level or proved CEA expression in tumor tissue~3. ≥ 18 years of age,~4. Given signed, written informed consent~5. Existence of at least one measurable tumor lesion by CT or MRI at the time of treatment, but no single lesion ≥ 8 cm in diameter.~6. At least 4 weeks recovery period after any major surgery, radiation, or chemotherapy, and total recovery from any acute toxicities associated with these prior treatments.~7. Life expectancy ≥ 3 months, Karnofsky performance status of ≥ 70%~8. Adequate hematology and renal function and hepatic function~9. Patients of childbearing potential must be willing to practice birth control during the study until at least 12 weeks after treatment, and women of childbearing potential must have a negative serum pregnancy test to enter the study~Exclusion Criteria :~1. Known central nervous system metastatic disease~2. \> 25% bone marrow involvement~3. CEA plasma levels \>2,000 ng/mL~4. Patients with successfully treated non-melanoma skin cancer or carcinoma in situ of the cervix are eligible, while patients with other prior malignancies must have had at least a 3-year disease-free interval.~5. HIV positive, hepatitis B-antigen positive, or hepatitis C positive patients~6. Known autoimmune disease,~7. Known history of unstable angina, myocardial infarction, or congestive heart failure present within 6 months or clinically significant cardiac arrhythmia (other than stable atrial fibrillation) requiring anti-arrhythmia therapy, no known history of clinical significant, active chronic obstructive pulmonary disease, or other moderate to severe chronic respiratory illness present within 6 months~8. Infection requiring intravenous antibiotic use within 1 week before inclusion,~9. Corticosteroids are not allowed within 2 weeks of study entry nor during the study except low doses (i.e., 20 mg/day of prednisone or equivalent) to treat nausea or other illness such as rheumatoid arthritis.~10. Patients who received a treatment containing a nitrosourea compound will not be enrolled for at least 6 weeks after the end of that treatment.~11. Known hypersensitivity to murine antibodies or proteins~12. Immunization against TF2 for patients who has already received injection of TF2~13. Adult patient unable to give informed consent because of intellectual impairment.~14. Adult patient protected by the French law~    -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- several cohorts (Type: EXPERIMENTAL): All patients will receive 3 injections of TF2 (the first: 14 mg/m², the second and the third:75 mg/m²). One day after each injection of TF2, the patient will receive a radiolabelled peptide (IMP-288) with Yttrium for therapeutic injectionThe First cohort will receive 555 MBq/m2 X 2 of 90-Y-IMP-288.:~All patient will receive 180 MBq of 111-In-IMP-288 for dosimetry analysis

Based on this trial design, predict the completion outcome and termination type (if applicable).